Elbion entered into alliances involving neurological products. In its first deal Elbion acquired a number of drug candidates from DrugAbuse Sciences. In the second deal, Elbion entered into a research and license agreement with Wyeth Pharmaceuticals for Elbion’s phosphodiesterase 10 program for CNS disorders.